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Purpose: To test patients from southern India for the presence of mutations that most commonly cause Leber congenital
amaurosis (LCA) in northern America.
Methods:  A  review  of  the  literature  identified  177  unique  LCA  causing  mutations  in  eight  different  genes:  aryl
hydrocarbon  receptor  interacting  protein-like  1  (AIPL1),  crumbs  homolog  1  (CRB1),  cone-rod  homeobox  (CRX),
guanylate cyclase 2D (GUCY2D), nephronophthisis 6 (NPHP6), retinol dehydrogenase 12 (RDH12), retinal pigment
epithelium-specific  protein  65  kDa  (RPE65),  and  retinitis  pigmentosa  GTPase  regulator  interacting  protein  1
(RPGRIP1). Allele-specific ligation assay and bidirectional sequencing were used to test 38 unrelated LCA patients from
southern India for 104 of these mutations, which contribute to more than 30% of the LCA cases in a northern American
population.
Results: Only one participant was found to harbor one of the 104 mutations in the allele-specific assay (homozygous
RPE65 Tyr368His). A mutation that was not part of the assay (homozygous RPE65 Tyr143Asp) was incidentally detected
in a second patient when an equivocal signal from one allele on the assay was followed up with automated DNA
sequencing.
Conclusions: Mutations that contribute to 30% of the LCA cases in northern America were detected in only 2.6% of LCA
cases in our cohort from southern India. There were no instances of IVS26 c.2991+1655 A>G in NPHP6, the most
commonly detected mutation in LCA. These data suggest that LCA in India is caused primarily by a different set of
mutations in the same genes associated with disease in northern America, or by mutations in other genes that have not yet
been discovered. Therefore, mutation-specific assays developed for European and northern American cohorts may not be
suited for testing LCA patients from India or other ethnically distinct populations.
Leber congenital amaurosis (LCA; OMIM 204000) is a
term used to describe a heterogenous and typically autosomal
recessive group of inherited retinal dystrophies characterized
by:  severe  visual  impairment  at  birth;  normal-appearing
retina; and profoundly reduced electroretinogram. Thirteen
genes  have  been  associated  with  LCA:  aryl  hydrocarbon
receptor  interacting  protein-like  1  (AIPL1)  [1],  crumbs
homolog  1  (CRB1)  [2],  cone-rod  homeobox  (CRX)  [3],
guanylate  cyclase  2D  (GUCY2D; RETGC1)  [4],  inosine
monophosphate  dehydrogenase  1  (IMPDH1)  [5],  Leber
congenital  amaurosis  5  (LCA5)  [6],  lecithin  retinol
acyltransferase  (LRAT)  [7],  nephronophthisis  6  (NPHP6;
CEP290) [8], retinol dehydrogenase 12 (RDH12) [9], retinal
degeneration  3  (RD3)  [10],  retinal  pigment  epithelium-
specific  protein  65  kDa  (RPE65)  [11],  and  retinitis
pigmentosa  GTPase  regulator  interacting  protein  1
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(RPGRIP1) [12], tubby like protein 1 (TULP1) [13,14]. The
frequency of disease-associated mutations among eight of
these genes has recently been assessed in large populations of
patients, using a range of technologies [15-18]. Many of the
variations detected in these studies were only rarely observed,
but nearly 100 different variations were detected in two or
more unrelated LCA patients [18].
In one study, mutations in GUCY2D, RPE65, and CRX
were detected in LCA patients from India, although at lower
frequency than previously reported in cohorts from northern
America [19]. In another study, mutations in RPE65 were
similarly detected in a smaller proportion of LCA patients
from India than in northern America [20]. Finally, a 2006
[10] study of RD3 identified a mutation in an Indian family,
but  found  no  examples  in  LCA  patients  from  northern
America. Although these studies have explored the role of
some previously discovered LCA genes in causing disease in
patients  from  India,  no  comprehensive  investigation  of
multiple genes has been performed on this population. We set
out to determine the frequencies of mutations associated with
LCA in the Indian population by testing 38 unrelated LCA
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1781patients from India for 104 previously identified mutations in
eight genes. In a 2007 study [18] of 642 northern American
LCA  patients,  49  of  these  104  mutations  cumulatively
contributed to more than 30% of LCA cases.
METHODS
The study received approval from the Ethical Review Board
of Aravind Eye Care System in India, and the Institutional
Review Board of the University of Iowa (Iowa City, IA).
Informed consent was obtained from all participants. Patients
were examined at the Aravind Eye Hospital (Madurai, India),
a regional facility serving a large area of southern India. As
such, patients and controls recruited for this study represent
an unselected sampling of the South Indian population. A total
of 41 unrelated individuals were enrolled in this study as
probands after a diagnosis of LCA. Probands were from 6
months to 12 years of age at enrollment (mean 5.0 years SD
±3.3), 24 female and 17 male, and in good health. Diagnosis
of  LCA  was  based  on  the  following  criteria:  1)  severely
reduced vision in both eyes that was recognized within two
years of birth; 2) relatively normal appearance of the retina;
3)  profoundly  reduced  or  nonrecordable  ISCEV
electroretinogram; and 4) absence of symptoms that would
suggest another disease. When possible, relatives were also
assessed  and  included  in  the  study  for  assessment  of
inheritance  phase.  A  total  of  84  family  members  were
enrolled, this included: 74 parents (0 affected; 33 male, 41
female; mean age 32.2 years SD±7.5), and 12 siblings (2
affected, 1 female aged 2 and 1 male aged 7; 10 unaffected, 6
male, and 4 female; mean age 10.7 years SD±4.0). Although
each proband was unrelated, consanguinity was identified
from histories in the families of 34 of 41 probands (83%).
Additionally, 25 unrelated healthy individuals were used as
control study subjects.
DNA  preparation:  Peripheral  blood  (approximately
10 ml) was collected using vacutainer EDTA (EDTA) tubes
(Becton-Dickinson,  Franklin  Lakes,  NJ),  and  DNA  was
extracted  by  salt  precipitation  [21].  Blood  samples  were
obtained from 41 unrelated affected individuals with LCA.
However, the concentration of the DNA obtained from three
of these participants was inadequate for the allele-specific
ligation  assay.  Consequently,  only  38  individuals  were
studied  with  both  the  allele-specific  ligation  assay  and
bidirectional sequencing of NPHP6, as will be described.
Allele-specific ligation assay: LCA-associated mutations
in  GUCY2D,  RPE65,  CRB1,  AIPL1,  CRX,  RDH12,  and
RPGRIP1 have been well characterized in northern American
populations [18]. A total of 177 previously reported mutations
in these genes were identified in a review of the literature. A
multiplexed allele-specific assay was designed to detect 138
of  these  mutations  using  the  SNPlex  platform  (Applied
Biosystems, Foster City, CA). Four of the 138 probes were
subsequently  found  to  be  benign  polymorphisms  [18],  or
evidence  for  disease  causing  status  was  inconclusive
(RPGRIP1  ARG812GLN).  These  probes  were  therefore
excluded  from  analysis.  Of  the  remaining  134  plausible
disease-causing alleles, technical limitations in the probe sets
meant the assay was unable to reliably detect either allele for
31 single nucleotide polymorphisms (SNPs). Consequently,
genotypic data from 103 SNPs were included in our analysis
(Table 1).
DNA  sample  preparation,  allele-specific  ligation,  and
post-ligation amplification were performed in 96 well plates
according  to  the  manufacturer’s  instructions  (SNPlex,
Applied Biosystems). PCR products were analyzed with a
3730 DNA sequencer and GeneMapper software (Applied
Biosystems). Allele status was initially assigned using custom
software  developed  at  the  University  of  Iowa,  and  allele
assignments were then confirmed manually. In some cases,
genotypes could not be reliably assigned because of low probe
signal strength (below 500 units for both normal and mutant
alleles). In total 51 of 3,914 genotypes (1.3%) were excluded
for this reason.
Positive  results  from  the  allele-specific  assay  were
verified by bidirectional sequencing of an amplimer spanning
the mutation in question. Confirmed mutations were assessed
in relatives of the probands to establish phase. Approximately
150 ng of each patient's DNA was used as template in a 30.0 µl
PCR containing the following: 3.0 µl 10X buffer (100 mM
Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl2), 9 mM of each
dCTP,  dATP,  dGTP,  and  dTTP,  9  pmole  of  each  primer
(Integrated DNA Technologies, Coralville, IA), and 0.9 units
of  DNA  polymerase  (Biolase,  Irvine,  CA).  Samples  were
denatured for 5 min at 94 °C and incubated for 35 cycles under
the following conditions: 94 °C for 30 s, 57 °C for 30 s, 72 °C
for 30 s in an MJ Research DNA thermocycler (BioRad,
Waltham,  MA).  PCR  products  were  purified  with  the
QIAquick  PCR  purification  kit  (Qiagen,  Valencia,  CA).
Sequencing was by dye-termination chemistry on an ABI
3730 DNA sequencer (Applied Biosystems), with subsequent
sequence  analysis  using  Sequencher  (Gene  Codes
Corporation, Ann Arbor, MI).
NPHP6 IVS26 c.2991+1655 mutation screening: In the
northern American population, the single most common LCA-
associated mutation is a deletion within intron 26 of NPHP6
(IVS26 c.2991+1655). Therefore a screen of this mutation
was conducted in parallel to the SNPlex assay. The presence
or  absence  of  the  c.2991+1655  mutation  in  intron  26  of
NPHP6 was assessed by bidirectional sequencing of genomic
DNA from each unrelated affected individual. Only those also
studied through the SNPlex assay (n=38) were included in this
report. Reaction conditions and sequence analysis were as
described in the previous section, except annealing conditions
were as follows: 30 s, with 65 °C for the first cycle, reducing
in temperature increments over the next nine cycles to 60 °C,
followed by 25 cycles at 60 °C.
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The presence or absence of 103 LCA-causing mutations was
successfully  assayed  with  an  allele-specific  ligation  assay
applied  to  38  patients  with  LCA  from  southern  India.
Genotype was determined in 3,755 of 3,914 tests, giving a
sensitivity of 95.9% for these alleles (Table 1; the 104th allele
was  assayed  only  by  bidirectional  sequencing,  please  see
paragraph  referring  to  NPHP6  below).  Of  these  disease-
causing mutations previously found in the northern American
population, only one example was identified in the cohort
from South India.
Patient ILCA-65–1 was homozygous for the mutation
(Tyr368His TAT>CAT) in RPE65 (Figure 1). This patient
presented at the Aravind Eye Institute at 3 years of age with
a history of poor vision. On examination, visual acuity was
20/80 (6/24) in the right eye and 20/200 (6/60) in the left eye.
Both  dark-adapted  scotopic  and  light-adapted  photopic
electroretinograms were nonrecordable. At age 9, pigmentary
changes were observed in the midperiphery of the the child’s
fundus.  Unaffected  parents  and  an  affected  sibling  were
available for study. The affected sibling was examined at 2
years of age and had visual acuities of 20/120 (6/36) in the
right  eye  and  20/160  (6/48)  in  the  left  eye,  extinguished
electroretinogram  responses,  and  pigmentary  retinopathy.
The  presence  of  this  mutation  was  confirmed  with
bidirectional DNA sequencing and the phase established in
available  samples  from  relatives.  Both  unaffected  parents
were  found  to  carry  a  heterozygous  Tyr368His  mutation,
while the affected sibling was homozygous for the Tyr368His
mutation.
In one instance, a mutation detected by the allele-specific
assay was not confirmed by subsequent DNA sequencing. A
Glu102STOP mutation in the RPE65 gene of one patient
(ILCA-100–1)  was  suggested  by  the  allele-specific  assay.
However, DNA sequencing showed this to be a false positive,
and  identified  a  different  RPE65  mutation  that  was  not
included  on  our  allele-specific  assay  (a  homozygous
Tyr143Asp TAC>GAC; Figure 2). Patient ILCA-100–1 was
first presented at the Aravind Eye Institute at 4 months of age
with the mother’s complaint that the infant was not fixating
on the her face. The patient was full term at birth, with normal
delivery and no remarkable antenatal or perinatal problems.
At 3 years of age, the patient’s examination was consistent
with  LCA:  severe  visual  impairment  with  nonrecordable
electroretinogram in both eyes, normal anterior segment, and
abnormal pigmentation in all four quadrants of the fundus with
mild temporal pallor of the discs in both eyes. At age 4, on a
recent follow-up, the subject was found to have a visual acuity
of  20/120  (6/36)  with  both  eyes  open,  and  has  achieved
otherwise normal developmental milestones. Again, family
history identified consanguinity, and both unaffected parents
were found to be heterozygous for the Tyr143Asp mutation.
The same cohort of 38 LCA patients were tested for the
c.2991+1655 A>G mutation in intron 26 of  NPHP6 with
bidirectional DNA sequencing. No instances of this mutation
were detected.
DISCUSSION
LCA  is  a  heterogeneous  condition  that  is  responsible  for
severe vision loss at birth. In the past 10 years great progress
has been made in identifying the genes that are responsible for
this condition. Mutations in the eight genes we studied in the
South  Indian  population  account  for  64%  of  LCA  in  the
United States [18].
In the current study, we explored the role of previously
discovered  LCA  mutations  in  a  cohort  of  patients  from
southern India by testing for the presence of 104 previously
reported mutations in eight LCA genes. While this particular
set of mutations has been associated with roughly 30% of LCA
cases in prior studies of patients from northern America, only
one proband in the cohort from southern India (ILCA-65–1)
was found to carry one of these 104 mutations previously
associated with LCA.
Figure 1. Clinical and molecular data for patient ILCA-65–1 and
family. The proband first presented for ophthalmic examination at 3
years of age. A: There were no recordable responses to light in the
electroretinogram. Examples shown are from the left eye for a dark-
adapted combined response and a light-adapted photopic response.
Arrowhead points to the timing of the 10-ms bright light pulse. B:
The family tree shows the proband (filled circle with arrow) and a
sibling  as  clinically  affected  and  both  parents  as  unaffected.  C:
Bidirectional  sequencing  showed  that  the  RPE65  Tyr368His
TAT>CAT mutation was homozygous in the affected proband (S1)
and affected sibling (S3), and was heterozygous in the mother (M)
and  father  (F).  Reverse  strand  sequence  around  RPE65  Tyr368
(caNatct) is shown against an ethnic unrelated and unaffected control
normal (NL).
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disease-causing mutation in the RPE65 gene that was not one
of the 103 alleles included in the original assay design. A
homozygous Tyr143Asp mutation was identified in subject
ILCA-100–1. Segregation of the mutation with disease in the
family  supports  the  Tyr143Asp  mutation  as  the  cause  of
disease  in  this  subject.  Although  we  had  not  previously
observed Tyr143Asp in LCA, we have observed Tyr143Asp
as  one  of  the  disease-causing  mutations  in  a  patient
categorized as having early onset retinitis pigmentosa. The
relatively  good  vision  for  an  LCA  patient  and  early
pigmentary changes of ILCA-100–1 illustrate the potential for
overlap in these clinical categories when the cause of disease
can be traced to mutations in the same gene.
The  lower  prevalence  of  mutations  in  the  cohort  of
patients from India is likely due in part to the high rate of novel
mutations  that  are   detected  in  LCA  genes.  In  a  prior 
study,  77%  of   disease-causing  variations   that   were 
detected  were  only  observed  once  [18]. Consequently,  it
is   plausible that   as   for   patient   ILCA-100–1,   many
patients in our study have novel  mutations   in   GUCY2D,
RPE65      CRB1, AIPL1, CRX, RDH12, RPGRIP ,  or
Figure 2. Clinical and molecular data for patient ILCA-100–1 and
family. The proband first presented for ophthalmic examination at 4
months of age. When the proband was 3 years old (A), there were no
recordable responses to light in the electroretinogram. Examples
shown are from the left eye for a dark-adapted combined response
and a light-adapted photopic response. Arrowhead marks the timing
of the 10-ms bright light pulse. B: The family tree shows the proband
(filled circle with arrow) as clinically affected, and both parents are
unaffected.  C:  Bidirectional  sequencing  showed  that  the  RPE65
Tyr143Asp TAC>GAC mutation was homozygous in the affected
proband (P) and was heterozygous in the mother (M) and father (F).
Reverse strand sequence around RPE65 Tyr143 (atNacta) is shown
against an ethnic unrelated and unaffected control normal (NL).
NPHP6 that were not included in the mutation-specific assay.
Alternatively, it is possible that a large proportion of LCA
cases from India are caused by mutations in novel or other
known LCA genes (LCA5 or RD3) [10,22]. Thus, our Indian
cohort of patients may be a useful resource for identifying
additional novel LCA genes or new mutations in known LCA
genes.  Furthermore,  our  research  suggests  that  mutation-
specific assays that are designed from studies of LCA patients
from one ethnic population are not the most efficient approach
for studying patients from different populations and ethnic
backgrounds.
The value of a detailed molecular screen of LCA patients
from  the  Indian  population  lies  in  genetic  counseling,
improved diagnosis and prognosis, the support this gives to
gene  discovery  efforts,  and,  more  recently,  in  identifying
patients  for  treatment.  In  both  families  with  a  molecular
diagnosis from this study, the mutation was in RPE65, so the
recent success of gene therapy for RPE65 presents a very real
hope of treatment in the future that will improve the vision of
these patients [23-25].
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